

Secondary Polycythemia in Hepatocellular Carcinoma: Treat or No Treat

by Ummi Maimunah

Submission date: 26-Apr-2023 07:14PM (UTC+0800)

Submission ID: 2076025971

File name: 18._Secondary_Polycythemia_in_Hepatocellular_Carcinoma.pdf (110.27K)

Word count: 2104

Character count: 13224

Secondary Polycythemia in Hepatocellular Carcinoma: Treat or No Treat

Poernomo Budi Setiawan, Ummi Maimunah, Nenci Siagian

Division of Gastroentero-hepatology, Department of Internal Medicine,
Faculty of Medicine Universitas Airlangga/Dr Soetomo General Hospital, Surabaya

Corresponding author:

Ummi Maimunah. Division of Gastroentero-hepatology, Department of Internal Medicine, Dr. Soetomo General Hospital. Jl. Mayjend Prof Dr. Moestopo No. 6-8 Surabaya Indonesia. Phone +62-31-5501614; facsimile: +62-31-5023865. E-mail: ummima@gmail.com

ABSTRACT

A 45-year man with a chronic hepatitis B virus (HBV) infection, elevated alphafetoprotein (AFP) 628ng/dL and Abdominal CT-scan features of Hepatocellular Carcinoma was admitted with polycythemia condition (haemoglobin 20.4g/dL, haematocrit 65.4%). Elevated of erythropoietin (EPO) serum level confirmed the polycythemia was because of hepatocellular carcinoma (HCC) as a paraneoplastic syndrome. Based on diagnosis criteria of HCC by Indonesian Association for the Study of the Liver 2017, the patient was diagnosed with HCC Barcelona clinic liver cancer (BCLC) B and was treated with trans arterial chemotherapy and embolization (TACE) with mixed doxorubicin. Aspirin 80mg once daily was given to patient to prevent thrombosis event. One month later after TACE, haemoglobin and haematocrite didn't improve. Then 4 months later the patient died of cardiovascular event in the last admission at district hospital.

Keywords: hepatocellular carcinoma (HCC), polycythemia, trans arterial chemotherapy and embolization (TACE)

ABSTRAK

Seorang pria 45 tahun dengan infeksi virus hepatitis B kronis (HBV), peningkatan alphafetoprotein (AFP) 628ng / dL dan fitur CT-scan Abdominal Hepatocellular Carcinoma dirawat dengan kondisi polisitemia (hemoglobin 20,4 g / dL, hematokrit 65,4%). Peningkatan kadar serum erythropoietin (EPO) mengkonfirmasi polisitemia yang disebabkan oleh karsinoma hepatoseluler (HCC) sebagai sindrom paraneoplastik. Berdasarkan kriteria diagnosis HCC oleh Asosiasi Indonesia untuk Studi Hati 2017, pasien didiagnosis dengan kanker hati klinik HCC Barcelona (BCLC) B dan dirawat dengan kemoterapi dan embolisasi arteri arteri (TACE) dengan doxorubicin campuran. Aspirin 80mg sekali sehari diberikan kepada pasien untuk mencegah kejadian trombosis. Satu bulan kemudian setelah TACE, hemoglobin dan hematokrit tidak membaik. Empat bulan kemudian pasien meninggal karena kejadian kardiovaskular dalam perawatan terakhir di rumah sakit kabupaten.

Kata kunci: karsinoma hepatoseluler (HCC), polisitemia, kemoterapi dan embolisasi trans arteri (TACE)

INTRODUCTION

Hepatocellular carcinoma (HCC) is a malignancy that arises from hepatocyte. HCC is the sixth most common cancer worldwide and the third most common

cause of death from cancer. Approximately three-fourth of cases occur in Asian countries because of a high prevalence of chronic infection with HBV. HCC is undoubtedly a great health threat in Asian region¹.

Polycythemia or erythrocytosis is a well-known paraneoplastic phenomenon in patients with HCC with incidence about 3-12%, but its pathogenesis remains uncertain. Recently, it has been reported that HCC cells are responsible for the production of erythropoietin (EPO), which leads to polycythemia in HCC patients². Polycythemia as well as the others paraneoplastic syndromes play a significant role in the progress of HCC and lead to poor prognosis in patient HCC especially in increasing the risk of thrombosis event due to hyperviscosity in patient HCC^{3,4}. The guideline of treatment of secondary polycythemia in HCC is not established yet.

CASE ILLUSTRATION

A 45-year man with history of hepatitis B admitted to our health centre due to upper right abdominal pain progressively since 4 months ago and headache intermittently since 2 months ago. On admission laboratory analysis showed haemoglobin 20.4g/dL, haematocrit 65.4% and elevated alphafetoprotein (AFP) 628 ng/dL. The abdominal ultrasound which was taken 2 month before admission showed HCC and the chest x-ray showed normal cardiac and pulmo. The abdomen MSCT with contrast which was also performed on admission revealing enhancing solid lesion +/- 12.0x12.9x13.2 cm at segmen V,VI, VII, VIII, feeded by right a.hepatica with early wash pattern at artery phase, early wash out pattern at venous phase and delay phase without thrombus or fistula, satellite nodul at segmen II (HCC). In order to investigate a polycythemia an examination of erythropoietin (EPO) serum level was conducted revealing higher than normal 280mU/mL (4.1-19.5 mU/mL). This value confirmed the secondary polycythemia due to HCC. Trans arterial chemotherapy and embolization (TACE) with mixed doxorubicin 50mg was performed as a recommended treatment of HCC and low dose aspirin 80mg was given as a prophylaxis of thrombotic risk due to polycythemia in this case. 1 month later after TACE and during low dose aspirin treatment, the haemoglobin and haematocrite didn't improve and 4 months later the patient died of cardiovascular event in the last admission at district hospital.

DISCUSSION

HCC is a primary cancer arising from hepatocytes in predominantly cirrhotic liver (70-90%) but it may not have cirrhosis before developing HCC, especially

hep.B virus (30%). Men are generally more susceptible than women (2:1). Upper right quadrant abdominal pain and abdominal mass are common clinical manifestations of HCC. The positive of hepatitis virus marker, elevated alphafetoprotein (AFP) > 400ng/dL and HCC features by abdominal ultrasound/CT scan can confirm the diagnosis of HCC based on diagnostic criteria by the Indonesia' liver researcher association 2017. The therapy is based on the stadium that consists of size, number of nodule, performance score and Child-pugh score^{5,6}.

Polycythemia or erythrocytosis is a blood disorder characterised by elevated haemoglobin (Hb) more than 18.5 g/dL (man)/ 16.5 g/dL (woman) or elevated haematocrit (Ht) more than 52% (man)/48% (woman) (Keohane). In general polycythemia is divided into two main group (1) Absolute polycythemia which includes primary polycythemia (polycythemia vera, Epo-receptor mutation,etc) and secondary polycythemia due to tumor-associated polycythemia (HCC, renal tumor, uterine myoma, etc) and hypoxia-associated polycythemia (congenital heart disease, chronic obstruction pulmonary disease, asthma,etc); (2) Relative polycythemia due to loss volume plasma, dehydration, etc. Patients are generally asymptomatic, but the symptoms they may experience are related to ischemia from hyperviscosity and thromobosis due to increased red blood mass. General symptoms may include fatigue, weakness and dyspnea and others signs and symptoms include hepatosplenomegaly, headache, vertigo and tinitus^{7,8,9,10}.

Patients with HCC that manifests paraneoplastic syndromes such as hypoglycemia, hypercholesterolemia and polycythemia usually has a larger tumor volume and high serum alpha-fetoprotein^{11,12,13}. Hwang et al. reported 20 (2.5%) of 792 chinese HCC patients presented with polycythemia then they found that 19 patients had either bi-lobar tumor involvement or a large tumor mass (50% whole liver) confined to one lobe of the liver¹². The pathogenesis of polycythemia in HCC is still unclear. Ke, et al, reported there is an underlying link between mitochondrial function and hypoxia inducible factor (HIF) alpha signaling, revealing a mechanism of polycythemia in HCC. Lack of alpha-ketoglutarate and prophyldhydroxylase makes HIF stable and induce over production of EPO then. EPO always binds to EPO receptor (EPOR) before transforms and activates the signaling of JAK-2 tranduction cascade that induce proliferation, stabilisation and differentiation of red blood cell. Thus, the new treatment using soluble EPO receptor to block EPO signaling^{2,14,15}.

10

There is a well defined association between polycythemia, rise in blood viscosity and the risk of thrombosis¹⁶. The 34 year follow-up of the framingham cohort reported an association between being in the group with the highest packed red cell volume (five groups in total) and the risk of cardiovascular mortality and morbidity was 1.6 ($p = 0.0018$) for women and 1.29 ($p = 0.019$) for men aged 35-64 years who were in this group³. Phlebotomy is an effective treatment modality for lowering hematocrit value in patients PV and secondary polycythemia but target hematocrit ($< 45\%$) was not achieved after a single phlebotomy.^{17,18} However, there is no study recommends routine phlebotomy for secondary polycythemia in HCC. It may be because repeated phlebotomies could cause iron deficiency with microcytic erythrocytes that can actually increase rather than decrease blood viscosity and somehow induce erythrocytosis due to compensatory effect.¹⁹ In healthy men, a single 500-mL whole-blood donation results in a substantial loss of heme iron (i.e., 200–250 mg) and decreases serum ferritin levels by 44%. Thus, phlebotomy without a proper monitoring of blood viscosity can potentially accentuate rather than decrease the risk of a cardiovascular or cerebrovascular accident. Recently the data showed therapeutic erythrocytapheresis (TEA) was clearly superior to traditional phlebotomy in terms of prolonging the period between one treatment and another, independent of the type of erythrocytosis and of the treatment group. For example, for the patients undergoing only phlebotomy, the treatment time interval was 51.66 ± 29.8 days, whereas for TEA patients it was 139 ± 49.5 ($p < 0.001$).^{20,21}

Low dose aspirin (80-100mg/day) is effective for prevention of arterial vascular events and for the primary prevention of venous thromboembolism²². In 2014, aspirin was demonstrated by the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) placebo-controlled randomized clinical trial, showing that low-dose aspirin can safely prevent thrombotic complications in patients with PV who have no contraindication to such treatment. Currently, hydroxyurea (HU) is recommended in PV patients who are at high risk of thrombosis, progressive disease, or in those who cannot tolerate frequent therapeutic phlebotomies. Based on results of a phase II study of The Polycythemia Vera Study Group (PVSG) trial, Hydroxyurea (HU), alone or in association with phlebotomy, was found efficacious and safe and is currently considered the first-line therapy in PV patients, but it has never been entered in controlled

trials of adequate size and duration to assess its long-term safety^{23,24}.

The case described here demonstrates a palliative treatment such as TACE didn't improve the polycythemia in HCC BCLC B. Low-dose aspirin was required to prevent the thrombotic event as long as the hematocrit $>45\%$. Therapeutic phlebotomy should be considered in emergency case when the patient shows signs and symptoms of thrombosis. In the last admission at district hospital the patient had symptoms of thrombotic unfortunately phlebotomy couldn't be done because of limitation source.

REFERENCES

1. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int* 2010;4:439-74.
2. Ke S, Chen S, Dong Z, Hong CS, Zhang Q, Tang L, et al. Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations. *Hepatology* 2017;65:134-51.
3. Gagnon, R. D. & Kannel, B. W. Hematocrit and the Risk of Cardiovascular Disease-The Framingham Study: A 34-year follow-up. *American Heart Journal* 1994;674-82.
4. Qu Q, Wang S, Chen S, Zhou L, Ja R. Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. *Am Surg* 2014;80:191-6.
5. Bisceglie AM, Befeler AS. Hepatic tumor and cysts. In: M, F. (ed.) *Sleisenger and Fordtran's Gastrointestinal and Liver Disease*, 10th ed. Philadelphia: Elsevier Inc. 2016.p.1603-1613.
6. PPHI 2017. konsensus nasional penatalaksanaan karsinoma sel hati, perhimpunan peneliti hati indonesia.
7. Keohane C, McMullin FM, Harrison C. The diagnosis and management of erythrocytosis. *BMJ* 2013;x:f6667.
8. Adamson WJ, Longo LD. Anemia and Polycythemia. In: Kasper DL, eds. *Harrison's Principles of Internal Medicine*, 19th ed. New York: McGraw Hill Education; 2015.p. 393-4.
9. Prchal, TJ. Primary and Secondary Erythrocytosis. Chapter 57. In: Kaushansky K, Lichtman MA, Prchal JT, et al, eds *Williams Hematology*. 9th ed. New York, NY: McGraw Hill Medical. 2015.
10. Tefferi A. Diagnostic approach to the patient with polycythemia. *UpToDate* 2018.
11. Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, Chiang JH, Lui WY, Chu CW, Lee SD. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. *Hepatogastroenterology* 2002;49:1315-9
12. Chang PE, Ong WC, Lui HF, Tan CK. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. *ISRN Oncol* 2013;684026.
13. Kew CM. Paraneoplastic phenomena in patients with hepatocellular carcinoma. *J Liver Res Disorder Ther* 2016;29-12.
14. Huh UY, Kim JH, Kim BH, Nam KD, Jang JY, Kim NH, et al. The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. *Korean J Hepatol* 2005;11:275-83.

15. Jokilehto, T. & Jaakkola, P. M. 2010. The role of HIF prolyl hydroxylases in tumour growth. *J Cell Mol Med* 2010;14:758-70.
16. Pearson TC, Weatherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative Polycythemia. *Lancet* 1978;2:1219-22.
17. Kong JH, Lee NS, Eom SH, Lee H, Han JY, Yoo H, et al. Assessment of effect of Phlebotomy in Patients with Polycythemia Vera and Secondary Polycythemia. *Korean J Blood Transfus* 2013;24:265-74.
18. Hyun JL, Kyung HS, Duyeal S, Sun ML. Optimal phlebotomy interval to change hematocrit levels in patients with polycythemia. *Korean J Blood Transfus* 2016;27:220-8.
19. Tso, C.S.A & Hua, P.S. Erythrocytosis in hepatocellular carcinoma: a compensatory phenomenon. *British J Haematol* 1974;28:147.
20. Holsworth ER, Weidman JJ, Sloop GD, St.Cyr AJ. Cardiovascular benefits of phlebotomy: relationship to changes in hemorheological variables. *Perfusion* 2013;29:x-x.
21. Vecchio S, Leonardo P, Musuraca V, D'Ettoris AR, Geremicca W. A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocytapheresis in patients with erythrocytosis. *Blood Transfus* 2007;5:20-23.
22. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose Aspirin in polycythemia vera. *N Eng J Med* 2004;350:114-24.
23. Ghirardi, A., Carobbio, A., Masciulli, A. & Barbui, T. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. *Blood Cancer Journal* 2018;8:5.

Secondary Polycythemia in Hepatocellular Carcinoma: Treat or No Treat

ORIGINALITY REPORT

17%

SIMILARITY INDEX

11%

INTERNET SOURCES

12%

PUBLICATIONS

8%

STUDENT PAPERS

PRIMARY SOURCES

- 1 Chen, Yong Peng, Xie Er Liang, Qi Zhang, Jie Peng, You Fu Zhu, Wei Qun Wen, and Jin Lin Hou. "Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B : FibroScan for chronic hepatitis B advanced fibrosis", *Journal of Gastroenterology and Hepatology*, 2012.
Publication 2%
- 2 care.diabetesjournals.org
Internet Source 2%
- 3 pesquisa.bvsalud.org
Internet Source 2%
- 4 Submitted to Northern Kentucky University
Student Paper 1%
- 5 Rüdiger Scharf. "Do we need antiplatelet therapy in thrombocytosis? Contra", *Hämostaseologie*, 2017
Publication 1%

6	Submitted to Salish Kootenai College Student Paper	1 %
7	media.neliti.com Internet Source	1 %
8	www.nejm.org Internet Source	1 %
9	"Rare Hematological Malignancies", Springer Nature, 2008 Publication	1 %
10	isn-iran.ir Internet Source	1 %
11	pure.uva.nl Internet Source	1 %
12	Qiang Qu, Shaobin Wang, Shuguang Chen, Li Zhou, Jing-An Rui. "Prognostic Role and Significance of Paraneoplastic Syndromes in Hepatocellular Carcinoma", The American Surgeon, 2020 Publication	1 %
13	Shelonitda S. Rose. "Cyanotic Congenital Heart Disease (CCHD) with Symptomatic Erythrocytosis", Journal of General Internal Medicine, 11/16/2007 Publication	1 %
14	docplayer.nl Internet Source	1 %

15 "Biomarkers in Liver Disease", Springer Science and Business Media LLC, 2017 1 %
Publication

16 Ayalew Tefferi, Lawrence A Solberg, Murray N Silverstein. "A clinical update in polycythemia vera and essential thrombocythemia", The American Journal of Medicine, 2000 1 %
Publication

17 www.intechopen.com 1 %
Internet Source

18 Chyntia Olivia Maurine Jasirwan, Alessa Fahira, Lianda Siregar, Imelda Loho. "The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia", BMC Gastroenterology, 2020 <1 %
Publication

Exclude quotes Off

Exclude matches Off

Exclude bibliography On

Secondary Polycythemia in Hepatocellular Carcinoma: Treat or No Treat

GRADEMARK REPORT

FINAL GRADE

/0

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4
